peptomyc logo

Contact information

Carrer de Natzaret, 115
+34.932543450 (ext. 8628)
Areas of activities
  • Drug development
  • Oncology

Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.

Products and services

Peptomyc technology and IP is founded on the knowledge accumulated by Dr. Soucek‘s lab on Omomyc, a dominant-negative Myc mutant that is the most efficacious and safe direct Myc inhibitor to date and that shows great therapeutic promise in a variety -if not all- cancer types. Omomyc was considered a proof of principle for many years, and its application was to be limited to gene therapy. However, Dr. Soucek’s lab has shown that the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cell lines. Peptomyc now aims to further develop the Omomyc peptide – and improved variants – into clinically viable therapeutics for the treatment of cancer patients. First clinical trials in lung and breast cancer patients are planned in 2020.

Areas of interest for future collaborations

Pharma and clinical research companies.